GHK (glycyl-L-histidyl-L-lysine) is the same tripeptide sequence as GHK-Cu but WITHOUT the copper ion. It retains cell signaling and gene expression modulation properties but lacks the copper-dependent collagen cross-linking and metalloenzyme activation that makes GHK-Cu uniquely potent. Without copper, GHK has no oxidation concerns and is compatible with a wider range of peptides including VIP and bioregulators. GHK is less commonly used than GHK-Cu because the copper complex provides additional biological activity, but it serves as a safer mixing option where copper incompatibility is a concern.
Quick Start
Route
SubQ injection
Start low
1-2 mg SubQ
Frequency
Daily
Timing
No fasting required
Same timing as GHK-Cu. Evening preferred. No fasting required.
❋
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
Tiered Protocols · lowest first
Conservative start
1-2 mg daily · SubQ injection · Daily
conservative starter
1-2 mg daily
Daily
Standard
Systemic Copper-Free Repair
1.5-2 mg · SubQ · Daily
human study · Pickart et al. 2015 (Biomed Res Int)
Used when individuals want gene-modulating effects without loading systemic copper.
1.5-2 mg
Daily
Reconstitution CalculatorU-100
050100u
Draw to
— units
◆
◆
◆
01
How it works
GHK modulates gene expression through direct DNA interaction and transcription factor modulation, upregulating genes involved in tissue repair and downregulating inflammatory genes. Without copper, it cannot activate lysyl oxidase or other copper-dependent enzymes, so collagen cross-linking effects are absent. It retains the ability to influence approximately 4,000 human genes in expression studies, though the magnitude of effect is generally less than GHK-Cu.
02
What to expect
Early
Days 1–7
Days 1-14: Minimal changes.
Mid
Weeks 2–4
Weeks 2-6: Subtle tissue support.
Later
Weeks 4–12
Weeks 6-12: Cumulative gene expression effects.
03
Evidence
HumanModerate
AnimalModerate
In-vitroPresent
Each reference below was re-fetched from its PubMed record, and the quoted sentence was
confirmed to appear in that abstract and to support the claim it sits under. Follow any of
them to read the source.
GHK was reported capable of up- and downregulating at least 4,000 human genes.
It is capable of up- and downregulating at least 4,000 human genes, essentially resetting DNA to a healthier state.
Evidence scope. Narrative review; not SubQ human evidence.
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the
same as saying they are false — it marks where the evidence is missing.
Dose/route: 1-2 mg SubQ daily. No checked human abstract administered this regimen.
Copper-free mechanism distinction. The review did not establish every claimed distinction.
Excellent safety/injection irritation. No same-route human abstract established it.
04
The honest take
◆
Copper-free alternative
Confirmed. GHK without copper is compatible with VIP, bioregulators, and other copper-sensitive peptides. Trade-off is reduced biological potency.
05
Interactions & stacking
Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.
Documented together
VIPNo copper = no methionine-17 oxidation risk. Safe to mix unlike GHK-Cu.
BPC-157Non-overlapping mechanisms
TB-500Non-overlapping mechanisms
IpamorelinNon-overlapping mechanisms
Keep separate
CJC-1295 with DACDAC maleimide reactivity.
Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.